CVE-2025-22375

Authentication Bypass in CyberAudit-Web

Description

An authentication bypass vulnerability was found in Videx's CyberAudit-Web. Through the exploitation of a logic flaw, an attacker could create a valid session without any credentials. This vulnerability has been patched in versions later than 9.5 and a patch has been made available to all instances of CyberAudit-Web, including the versions that are End of Maintenance (EOM). Anyone that requires support with the resolution of this issue can contact support@videx.com for assistance.

Category

9.3
CVSS
Severity: Critical
CVSS 4.0 •
EPSS 0.11%
Third-Party Advisory divd.nl Third-Party Advisory divd.nl
Affected: Videx Inc. CyberAudit-Web
Published at:
Updated at:

References

Link Tags
https://csirt.divd.nl/CVE-2025-22375 third party advisory
https://csirt.divd.nl/DIVD-2024-00043/ third party advisory

Frequently Asked Questions

What is the severity of CVE-2025-22375?
CVE-2025-22375 has been scored as a critical severity vulnerability.
How to fix CVE-2025-22375?
To fix CVE-2025-22375, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2025-22375 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2025-22375 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2025-22375?
CVE-2025-22375 affects Videx Inc. CyberAudit-Web.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.